Allschwil
Switzerland
23
2025-11-06
The entities that hold a legal rights for patent applications filed by inventor VON RAUMER Markus:
Markus VON RAUMER from Allschwil, CH has applied for patents for these inventions. The list has both pending applications and granted patents:
CRYSTALLINE FORMS OF SODIUM (5-(4-BROMOPHENYL)-6-(2-((5-BROMOPYRIMIDIN-2-YL)OXY)ETHOXY)PYRIMIDIN-4-YL)(SULFAMOYL)AMIDE
#2 | 2025-05-22Crystalline Forms
#3 | 2024-04-11A CRYSTALLINE FORM OF (4-METHYL-2-[1,2,3]TRIAZOL-2-YL-PHENYL)-[(R)-3-(3-[1,2,3]TRIAZOL-2-YL-BENZYL)-MORPHOLIN-4-YL]-METHANONE
#4 | 2023-12-07Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan
#5 | 2023-11-23A STABLE CRYSTALLINE HYDRATE OF CLAZOSENTAN DISODIUM SALT
#6 | 2023-08-17AQUEOUS PHARMACEUTICAL COMPOSITION COMPRISING A P2Y12 RECEPTOR ANTAGONIST
#7 | 2022-09-01Crystalline forms
#8 | 2022-08-25PHARMACEUTICAL COMPOSITION COMPRISING A TETRAHYDROPYRAZOLOPYRIMIDINONE COMPOUND
#9 | 2022-03-03Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
#10 | 2021-09-30Crystalline form of N-[1-(5-cyano-pyridin-2-ylmethyl)-1 H-pyrazol-3-yl]-2- [4-(1-trifluoromethyl-cyclopropyl)-phenyl-acetamide
#11 | 2021-07-08Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan
#12 | 2021-04-22Crystalline forms of the CXCR7 receptor antagonist (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide
#13 | 2021-01-14Crystalline forms
#14 | 2020-05-28Crystalline form of N-[1-(5-cyano-pyridin-2- ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide
#15 | 2020-02-27Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
#16 | 2020-01-16Crystalline forms
#17 | 2020-01-02Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan
#18 | 2019-02-14Crystalline forms
#19 | 2018-01-04Crystalline salt form of (S)-(2-(6 chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
#20 | 2016-12-22Crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[D]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists
#21 | 2016-12-08Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
#22 | 2011-10-27Salts of isobutyric acid (1 R*, 2R*, 4R*)-2-(2-{[3-(4,7-dimethoxy-1 H-benzoimidazol-2-yl)-methyl-amino}-ethyl)-5-phenyl-bicyclo[2.2.2]oct-5-en-2-yl ester
#23 | 2011-08-11Crystalline forms of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-0-tolyl-thiazolidin-4-one
1730521 ⎘